Results 71 to 80 of about 96,616 (241)

Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model

Health Technology Assessment
Background Multiple sclerosis is an immune-mediated inflammatory disease, causing long-term disability in young adults. Most cases begin as relapsing–remitting multiple sclerosis. Some people have a form of relapsing–remitting multiple sclerosis known as
Catalina Lopez Manzano, Ayman Sadek, Chris Cooper, Eve Tomlinson, Hanyu Wang, Claire Rice, Emma Tallantyre, Ananya Rao-Middleton, Penny Whiting, Howard Thom   +9 more
doaj   +1 more source

Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients. [PDF]

Int J Mol Sci, 2022
Nötzel M, Werder LI, Ziemssen T, Akgün K.   +3 more
europepmc   +1 more source

Ocrelizumab as first-line therapy in highly active relapsing-remitting multiple sclerosis

Journal of the Neurological Sciences
In recent years, early use of highly effective disease modifying immunotherapies in relapsing-remitting multiple sclerosis (RRMS) demonstrated superior efficacy in preventing disability progression. For this study, we investigated ocrelizumab as first line therapy of RRMS in a monocentric, retrospective study.
Kvartskhava, Tamar, Freudenstein, David, Sarmiento, Nicolas, Angstwurm, Klemens, Linker, Ralf, Lee, De-Hyung   +5 more
openaire   +3 more sources

Intracerebral Hemorrhage Induces Monocyte TNF Signaling in Patients That Is Suppressed by BAF312

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Intracerebral hemorrhage (ICH) causes high morbidity and mortality, with neurotoxic inflammation driven by infiltrating monocytes. This study is an in‐depth longitudinal examination of the immune response during the first week of ICH in the presence and absence of the immunomodulatory drug BAF312 (Siponimod).
Jonathan Howard DeLong, Sebastian Díaz‐Pérez, Kevin Navin Sheth, Jang‐Ho Cha, C. J. Malanga, Patricia G. M. Wagner, Nicole Pezous, Aurelie Hanin, Kyle B. Walsh, H. E. Hinson, Lauren Hachmann Sansing   +10 more
wiley   +1 more source

Patient and Neurologist Preferences in the United States for Relapsing-Remitting Multiple Sclerosis Treatments: Findings from a Discrete Choice Experiment

Patient Preference and Adherence, 2021
Jinender Kumar,1 M Janelle Cambron-Mellott,2 Tom Tencer,1 Oliver Will,2 deMauri S Mackie,2 Kathleen Beusterien2 1Worldwide Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA; 2RWE Data and Analytics, Kantar Health, New York,
Kumar J, Cambron-Mellott MJ, Tencer T, Will O, Mackie dS, Beusterien K   +5 more
doaj  

The Role of Astrocytes in Multiple Sclerosis

Frontiers in Immunology, 2018
The role traditionally assigned to astrocytes in the pathogenesis of multiple sclerosis (MS) lesions has been the formation of the glial scar once inflammation has subsided.
Gerald Ponath, Calvin Park, David Pitt
doaj   +1 more source

Stage‐Dependent β‐Synuclein Links MRI and Cognitive Decline in Alzheimer's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Synaptic degeneration drives cognitive decline in Alzheimer's disease (AD), but synaptic biomarkers are scarce. Brain‐enriched β‐synuclein emerged as a synaptic damage marker. We investigated its diagnostic, prognostic, and structural correlates across the AD continuum.
Ulaş Ay, Merve Alaylioglu, Erdi Sahin, Sanem Sultan Yoruk Oner, Gulce Iskan, Gulce Cosku Yilmaz Cakan, Gozde Kizilates‐Evin, Emre Hari, Elif Kurt, Erdinc Dursun, Basar Bilgic, Hasmet Hanagasi, Hakan Gurvit, Tamer Demiralp, Duygu Gezen‐Ak, Bedia Samanci   +15 more
wiley   +1 more source

Diffusion tensor tomography with tractography in assessment of the pyramidal system in patients with highly active multiple sclerosis

Неврология, нейропсихиатрия, психосоматика
Objective: to study the pyramidal tract in patients with highly active multiple sclerosis (HAMS) during treatment switching from first-line MS therapy to second-line therapy due to suboptimal response.Material and methods.
A. N. Peshkin, G. T. Toniya, E. A. Stepanova, V. Yu. Lizhdvoi, S. V. Kotov   +4 more
doaj   +1 more source

Anti‐CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non‐Active Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To determine whether discontinuing anti‐CD20 therapy in people with relapsing‐onset MS aged over 50 is associated with an increased risk of relapse, inflammatory activity, confirmed disability accrual, and serious infection compared with continuing therapy.
Alexia Moukhine, Fabien Rollot, Romain Casey, Nicolas Collongues, Sandra Vukusic, Guillaume Mathey, Anne Laure Dubessy, Jonathan Ciron, Jérôme De Seze, Aurélie Ruet, Pierre Labauge, Arnaud Kwiatkowski, Hélène Zephir, Caroline Papeix, Gilles Defer, Christine Lebrun‐Frenay, David Axel Laplaud, Eric Berger, Eric Thouvenot, Jean Pelletier, Abdullatif Al Khedr, Olivier Casez, Bertrand Bourre, Abir Wahab, Laurent Magy, Jean‐Philippe Camdessanché, Ines Doghri, Solène Moulin, Mariana Sarov Rivière, Karolina Hankiewicz, Amélie Dos Santos, Corinne Pottier, Eric Manchon, Jennifer Aboab, Maia Tchikviladze, Thomas David, Gilles Edan, Emmanuelle Le Page, Laure Michel, Anne Kerbrat, OFSEP Investigators   +40 more
wiley   +1 more source

TEAMS (Tele-Exercise and Multiple Sclerosis), a Tailored Telerehabilitation mHealth App: Participant-Centered Development and Usability Study

JMIR mHealth and uHealth, 2018
BackgroundPeople with multiple sclerosis face varying levels of disability and symptoms, thus requiring highly trained therapists and/or exercise trainers to design personalized exercise programs.
Thirumalai, Mohanraj, Rimmer, James H, Johnson, George, Wilroy, Jereme, Young, Hui-Ju, Mehta, Tapan, Lai, Byron   +6 more
doaj   +1 more source